- Home
- VGI vs QNCX Comparison
VGI vs QNCX Comparison
Compare VGI & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VGI
- QNCX
- Stock Information
- Founded
- VGI 2012
- QNCX 2012
- Country
- VGI United States
- QNCX United States
- Employees
- VGI N/A
- QNCX N/A
- Industry
- VGI Investment Managers
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VGI Finance
- QNCX Health Care
- Exchange
- VGI Nasdaq
- QNCX Nasdaq
- Market Cap
- VGI N/A
- QNCX 47.7M
- IPO Year
- VGI N/A
- QNCX 2019
- Fundamental
- Price
- VGI $7.89
- QNCX $1.58
- Analyst Decision
- VGI
- QNCX Strong Buy
- Analyst Count
- VGI 0
- QNCX 5
- Target Price
- VGI N/A
- QNCX $8.00
- AVG Volume (30 Days)
- VGI 46.0K
- QNCX 334.5K
- Earning Date
- VGI 01-01-0001
- QNCX 08-12-2025
- Dividend Yield
- VGI 12.66%
- QNCX N/A
- EPS Growth
- VGI N/A
- QNCX N/A
- EPS
- VGI N/A
- QNCX N/A
- Revenue
- VGI N/A
- QNCX N/A
- Revenue This Year
- VGI N/A
- QNCX N/A
- Revenue Next Year
- VGI N/A
- QNCX N/A
- P/E Ratio
- VGI N/A
- QNCX N/A
- Revenue Growth
- VGI N/A
- QNCX N/A
- 52 Week Low
- VGI $6.68
- QNCX $0.51
- 52 Week High
- VGI $7.99
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- VGI 63.10
- QNCX 61.71
- Support Level
- VGI $7.82
- QNCX $1.48
- Resistance Level
- VGI $7.97
- QNCX $1.71
- Average True Range (ATR)
- VGI 0.07
- QNCX 0.13
- MACD
- VGI 0.01
- QNCX 0.00
- Stochastic Oscillator
- VGI 82.98
- QNCX 69.05
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.